Modeling hepatitis C virus kinetics during liver transplantation reveals the role of the liver in virus clearance

  1. Louis Shekhtman
  2. Miquel Navasa
  3. Natasha Sansone
  4. Gonzalo Crespo
  5. Gitanjali Subramanya
  6. Tje Lin Chung
  7. E Fabian Cardozo-Ojeda
  8. Sofia Pérez-del-Pulgar
  9. Alan S Perelson
  10. Scott J Cotler
  11. Xavier Forns
  12. Susan L Uprichard  Is a corresponding author
  13. Harel Dahari  Is a corresponding author
  1. Loyola University Medical Center, Stritch School of Medicine, United States
  2. University of Barcelona, Spain
  3. University of Illinois, Chicago, United States
  4. Fred Hutchinson Cancer Research Center, United States
  5. Los Alamos National Laboratory, United States

Abstract

While the liver, specifically hepatocytes, are widely accepted as the main source of hepatitis C virus (HCV) production, the role of the liver/hepatocytes in clearance of circulating HCV remains unknown. Frequent HCV kinetic data were recorded and mathematically modeled from 5 liver-transplant patients throughout the anhepatic (absence of liver) phase and for 4 hours post-reperfusion. During the anhepatic phase, HCV remained at pre-anhepatic levels (n=3) or declined (n=2) with t1/2~1h. Immediately post-reperfusion, virus declined in a biphasic manner in 4 patients consisting of a rapid decline (t1/2=5min) followed by a slower decline (t1/2=67min). Consistent with the majority of patients in the anhepatic phase, when we monitored HCV clearance at 37°C from culture medium in the absence/presence of chronically infected hepatoma cells that were inhibited from secreting HCV, the HCV t1/2 in cell culture was longer in the absence of chronically HCV-infected cells. The results suggest that the liver plays a major role in the clearance of circulating HCV and that hepatocytes may be involved.

Data availability

All data generated or analyzed during this study are included in the manuscript and supporting files

Article and author information

Author details

  1. Louis Shekhtman

    Division of Hepatology, Department of Medicine, Loyola University Medical Center, Stritch School of Medicine, Maywood, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5273-8363
  2. Miquel Navasa

    Liver Unit, Hospital Clínic, IDIBAPS and CIBEREHD, University of Barcelona, Barcelona, Spain
    Competing interests
    No competing interests declared.
  3. Natasha Sansone

    Department of Microbiology and Immunology, University of Illinois, Chicago, Chicago, United States
    Competing interests
    No competing interests declared.
  4. Gonzalo Crespo

    Liver Unit, Hospital Clínic, IDIBAPS and CIBEREHD, University of Barcelona, Barcelona, Spain
    Competing interests
    No competing interests declared.
  5. Gitanjali Subramanya

    Division of Hepatology, Department of Medicine, Loyola University Medical Center, Stritch School of Medicine, Maywood, United States
    Competing interests
    No competing interests declared.
  6. Tje Lin Chung

    Division of Hepatology, Department of Medicine, Loyola University Medical Center, Stritch School of Medicine, Maywood, United States
    Competing interests
    No competing interests declared.
  7. E Fabian Cardozo-Ojeda

    Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8690-9896
  8. Sofia Pérez-del-Pulgar

    Liver Unit, Hospital Clínic, IDIBAPS and CIBEREHD, University of Barcelona, Barcelona, Spain
    Competing interests
    No competing interests declared.
  9. Alan S Perelson

    Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, United States
    Competing interests
    No competing interests declared.
  10. Scott J Cotler

    Division of Hepatology, Department of Medicine, Loyola University Medical Center, Stritch School of Medicine, Maywood, United States
    Competing interests
    No competing interests declared.
  11. Xavier Forns

    3Liver Unit, Hospital Clínic, IDIBAPS and CIBEREHD, University of Barcelona, Barcelona, Spain
    Competing interests
    Xavier Forns, XF acted as advisor for Gilead and AbbVie.
  12. Susan L Uprichard

    Division of Hepatology, Department of Medicine, Loyola University Medical Center, Stritch School of Medicine, Maywood, United States
    For correspondence
    suprichard@luc.edu
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5691-1557
  13. Harel Dahari

    Division of Hepatology, Department of Medicine, Loyola University Medical Center, Stritch School of Medicine, Maywood, United States
    For correspondence
    hdahari@luc.edu
    Competing interests
    No competing interests declared.

Funding

National Institute of Allergy and Infectious Diseases (R01-AI078881)

  • Susan L Uprichard

National Institute of Allergy and Infectious Diseases (R01-AI116868)

  • Alan S Perelson

Instituto de Salud Carlos III (PI15/00151 and PI13/00155)

  • Xavier Forns

Secretaria d'Universitats i Recerca del Departament d'Economia i Coneixement (grant 2017_SGR_1753)

  • Xavier Forns

CERCA Programme/Generalitat de Catalunya

  • Xavier Forns

Germany Academic Exchange Service

  • Tje Lin Chung

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: The study was approved by the Ethics Committee at Hospital Clinic Barcelona (Record 2010/5810) and all patients provided a written informed consent.

Copyright

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Metrics

  • 545
    views
  • 89
    downloads
  • 4
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Louis Shekhtman
  2. Miquel Navasa
  3. Natasha Sansone
  4. Gonzalo Crespo
  5. Gitanjali Subramanya
  6. Tje Lin Chung
  7. E Fabian Cardozo-Ojeda
  8. Sofia Pérez-del-Pulgar
  9. Alan S Perelson
  10. Scott J Cotler
  11. Xavier Forns
  12. Susan L Uprichard
  13. Harel Dahari
(2021)
Modeling hepatitis C virus kinetics during liver transplantation reveals the role of the liver in virus clearance
eLife 10:e65297.
https://doi.org/10.7554/eLife.65297

Share this article

https://doi.org/10.7554/eLife.65297

Further reading

    1. Ecology
    2. Microbiology and Infectious Disease
    Benedikt M Mortzfeld, Shakti K Bhattarai, Vanni Bucci
    Short Report

    Interspecies interactions involving direct competition via bacteriocin production play a vital role in shaping ecological dynamics within microbial ecosystems. For instance, the ribosomally produced siderophore bacteriocins, known as class IIb microcins, affect the colonization of host-associated pathogenic Enterobacteriaceae species. Notably, to date, only five of these antimicrobials have been identified, all derived from specific Escherichia coli and Klebsiella pneumoniae strains. We hypothesized that class IIb microcin production extends beyond these specific compounds and organisms. With a customized informatics-driven approach, screening bacterial genomes in public databases with BLAST and manual curation, we have discovered 12 previously unknown class IIb microcins in seven additional Enterobacteriaceae species, encompassing phytopathogens and environmental isolates. We introduce three novel clades of microcins (MccW, MccX, and MccZ), while also identifying eight new variants of the five known class IIb microcins. To validate their antimicrobial potential, we heterologously expressed these microcins in E. coli and demonstrated efficacy against a variety of bacterial isolates, including plant pathogens from the genera Brenneria, Gibbsiella, and Rahnella. Two newly discovered microcins exhibit activity against Gram-negative ESKAPE pathogens, i.e., Acinetobacter baumannii or Pseudomonas aeruginosa, providing the first evidence that class IIb microcins can target bacteria outside of the Enterobacteriaceae family. This study underscores that class IIb microcin genes are more prevalent in the microbial world than previously recognized and that synthetic hybrid microcins can be a viable tool to target clinically relevant drug-resistant pathogens. Our findings hold significant promise for the development of innovative engineered live biotherapeutic products tailored to combat these resilient bacteria.

    1. Microbiology and Infectious Disease
    Francesca Torelli, Diogo M da Fonseca ... Moritz Treeck
    Research Article

    Toxoplasma gondii is an intracellular parasite that subverts host cell functions via secreted virulence factors. Up to 70% of parasite-controlled changes in the host transcriptome rely on the MYR1 protein, which is required for the translocation of secreted proteins into the host cell. Mice infected with MYR1 knock-out (KO) strains survive infection, supporting a paramount function of MYR1-dependent secreted proteins in Toxoplasma virulence and proliferation. However, we have previously shown that MYR1 mutants have no growth defect in pooled in vivo CRISPR-Cas9 screens in mice, suggesting that the presence of parasites that are wild-type at the myr1 locus in pooled screens can rescue the phenotype. Here, we demonstrate that MYR1 is not required for the survival in IFN-γ-activated murine macrophages, and that parasites lacking MYR1 are able to expand during the onset of infection. While ΔMYR1 parasites have restricted growth in single-strain murine infections, we show that the phenotype is rescued by co-infection with wild-type (WT) parasites in vivo, independent of host functional adaptive immunity or key pro-inflammatory cytokines. These data show that the major function of MYR1-dependent secreted proteins is not to protect the parasite from clearance within infected cells. Instead, MYR-dependent proteins generate a permissive niche in a paracrine manner, which rescues ΔMYR1 parasites within a pool of CRISPR mutants in mice. Our results highlight an important limitation of otherwise powerful in vivo CRISPR screens and point towards key functions for MYR1-dependent Toxoplasma-host interactions beyond the infected cell.